News
-
-
COMMUNIQUÉ DE PRESSE
PharmaNest to Present Seven Digital Pathology and AI Communications and Abstracts at the International Liver Congress — EASL 2024, Including Analytical and Clinical Validation
PharmaNest showcases FibroNest Ph-FCS digital biomarker for quantifying fibrosis severity and its clinical utility in Phase 2 and Phase 3 studies for patients with Metabolic Associated Steatohepatitis at International Liver Congress - EASL -
COMMUNIQUÉ DE PRESSE
2-10 Home Buyers Warranty Celebrates National Homeownership Month and Continuing Growth With Enhanced Client Experiences
2-10 Home Buyers Warranty celebrates National Homeownership Month by offering enhanced experiences through their product offerings and industry-leading services -
COMMUNIQUÉ DE PRESSE
ONESTONE HOLDINGS Achieves Breakthrough in Green Hydrogen Production at Sea With Vertical Wind Turbines
ONESTONE HOLDINGS successfully produces green hydrogen on a ship with vertical wind turbines, revolutionizing clean energy production at sea. The innovative approach paves the way for affordable and sustainable green energy -
-
-
COMMUNIQUÉ DE PRESSE
Onramp Hires Mark Connors as Managing Director, Head of Global Macro Strategy to Accelerate Bitcoin Institutional Adoption
Onramp appoints Mark Connors as Managing Director, Head of Global Macro Strategy to drive institutional adoption of Bitcoin and enhance its role in portfolios. Connors brings 35 years of experience in liquid markets -
-
-
COMMUNIQUÉ DE PRESSE
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
TuHURA and Kintara announce positive results from TuHURA's Phase 1b trial evaluating IFx-2.0 in ICI naïve patients with advanced MCC and cSCC, overcoming resistance to ICI therapy. Data presented at 2024 ASCO Annual Meeting
